ReviewInternational journal of molecular sciences2017
Aptamers and Glioblastoma: Their Potential Use for Imaging and Therapeutic Applications.
Review in International journal of molecular sciences, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Aptamers Structure Flexibility Is Crucial to EGFR Inhibition Function.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Innovative aptamer approaches in glial tumor diagnostics and therapy: Progress and future directions.Molecular therapy. Nucleic acids · 2025Review
- A PET-CT study of the uptake of labeled aptamers [Frontiers in oncology · 2025Article
- Aptamers for Brain Tumors: A Therapeutic Agent for Effectively Crossing the Blood-Brain Barrier.Current molecular medicine · 2025Article
- Natural Food Components as Biocompatible Carriers: A Novel Approach to Glioblastoma Drug Delivery.Foods (Basel, Switzerland) · 2024Review
- Aptamers in neuro-oncology: An emerging therapeutic modality.Neuro-oncology · 2024Review
- Bioaffinity Nanoprobes for Foodborne Pathogen Sensing.Micromachines · 2023Article
- Application of aptamer functionalized nanomaterials in targeting therapeutics of typical tumors.Frontiers in bioengineering and biotechnology · 2023Review
- Advances in magnetic resonance imaging contrast agents for glioblastoma-targeting theranostics.Regenerative biomaterials · 2021Review
- Neuroblastoma GD2 Expression and Computational Analysis of Aptamer-Based Bioaffinity Targeting.International journal of molecular sciences · 2021Review
- Aptamers: Cutting edge of cancer therapies.Molecular therapy : the journal of the American Society of Gene Therapy · 2021Review
- Tumor Cell-Specific 2'-Fluoro RNA Aptamer Conjugated withInternational journal of molecular sciences · 2021Article
- Lipid-Based Nanocarriers for The Treatment of Glioblastoma.Advanced nanobiomed research · 2021Article
- Review
- Aptamer-Based In Vivo Therapeutic Targeting of Glioblastoma.Molecules (Basel, Switzerland) · 2020Review
- The Role of RNA and DNA Aptamers in Glioblastoma Diagnosis and Therapy: A Systematic Review of the Literature.Cancers · 2020Review
- Analysis of clinical characteristics of macrophage capping protein (CAPG) gene expressed in glioma based on TCGA data and clinical experiments.Oncology letters · 2019Article
- Radiolabelled Aptamers for Theranostic Treatment of Cancer.Pharmaceuticals (Basel, Switzerland) · 2018Review
- Bispecific therapeutic aptamers for targeted therapy of cancer: a review on cellular perspective.Journal of molecular medicine (Berlin, Germany) · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glioblastoma is a highly aggressive primary brain tumour, renowned for its infiltrative growth and varied genetic profiles. The current treatment options are insufficient, and their off-target effects greatly reduce patient quality of life. The major challenge in improving glioblastoma diagnosis and treatment involves the development of a targeted imaging and drug delivery platform, capable of circumventing the blood brain barrier and specifically targeting glioblastoma tumours. The unique properties of aptamers demonstrate their capability of bridging the gap to the development of successful diagnosis and treatment options, where antibodies have previously failed. Aptamers possess many characteristics that make them an ideal novel imaging and therapeutic agent for the treatment of glioblastoma and other brain malignancies, and are likely to provide patients with a better standard of care and improved quality of life. Their target sensitivity, selective nature, ease of modification and low immunogenicity make them an ideal drug-delivery platform. This review article summarises the aptamers previously generated against glioblastoma cells or its identified biomarkers, and their potential application in diagnosis and therapeutic targeting of glioblastoma tumours.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.